8-K: BioCardia Faces Nasdaq Delisting Notice Due to Stockholders' Equity Below Minimum Requirement

BioCardia, Inc. received a notice from Nasdaq for failing to meet the minimum stockholders' equity requirement for continued listing.

Summary

• BioCardia, Inc. received a notification from Nasdaq on April 1, 2025, indicating non-compliance with Nasdaq Listing Rule 5550(b)(1) due to stockholders' equity of $837,000 as of December 31, 2024, falling below the required $2.5 million.
• The company has until May 16, 2025, to submit a plan to Nasdaq to regain compliance.
• If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from April 1, 2025, to demonstrate compliance.
• The notice does not immediately affect the listing or trading of BioCardia's common stock, which will continue under the symbol BCDA.
• BioCardia intends to submit a plan to Nasdaq, which will assess the plan's likelihood of success, the company's compliance history, reasons for non-compliance, financial condition, and public disclosures.
• If Nasdaq rejects the plan, BioCardia can request a hearing with a Nasdaq Hearings Panel.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice, indicating financial distress and uncertainty about the company's future on the Nasdaq Capital Market.

Positives

• The notice has no immediate effect on the listing or trading of BioCardia's common stock.
• BioCardia intends to submit a plan to regain compliance with Nasdaq Listing Rules.
• The company has the opportunity to present its case to a Nasdaq Hearings Panel if its initial plan is rejected.

Negatives

• BioCardia is not in compliance with Nasdaq's minimum stockholders' equity requirement.
• The company's stockholders' equity was significantly below the required $2.5 million, standing at $837,000 as of December 31, 2024.
• There is a risk that Nasdaq may not accept BioCardia's plan to regain compliance, potentially leading to delisting.

Risks

• BioCardia may not meet the minimum stockholders' equity requirement in the required timeframe.
• The company may not otherwise meet the requirements for continued listing under the Nasdaq Listing Rules in the future.
• Nasdaq may not grant the company relief from delisting if necessary.
• The company may not ultimately meet applicable Nasdaq requirements even if relief is initially granted.

Future Outlook

The company intends to submit a plan to Nasdaq to regain compliance with the minimum stockholders' equity requirement. However, there is no guarantee that Nasdaq will accept the plan or that the company will be able to meet the requirements for continued listing.

Industry Context

Delisting notices are not uncommon for companies facing financial difficulties, particularly in the biotechnology sector where research and development costs can be substantial. Companies in similar situations often explore options such as reverse stock splits, capital raises, or strategic mergers to regain compliance.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining Nasdaq listing compliance due to volatile stock prices and the need for significant capital investment.
• Companies like Geron Corporation and Ocugen Inc. have faced similar delisting warnings in the past and have implemented strategies such as reverse stock splits or raising additional capital to regain compliance.
• The success of BioCardia's plan will depend on its ability to demonstrate a clear path to profitability and improved financial stability, similar to how other companies have successfully navigated delisting threats.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the stock price and liquidity.
• Employees may experience uncertainty regarding the company's future and job security.
• The company's ability to raise capital and fund its operations could be affected.

Next Steps

• BioCardia needs to submit a plan to Nasdaq by May 16, 2025, to regain compliance.
• Nasdaq will review the plan and determine whether to grant an extension of up to 180 days to evidence compliance.
• If the plan is rejected, BioCardia may request a hearing with a Nasdaq Hearings Panel.

Key Dates

Keywords

Nasdaq, delisting, compliance, stockholders' equity, BioCardia, BCDA, listing rule